Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
Apply
CD5 CAR NK Cells
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step